Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study.
Flaadt T, Rehm J, Simon T, Hero B, Ladenstein RL, Lode HN, Grabow D, Nolte S, Crazzolara R, Greil J, Ebinger M, Abele M, Holzer U, Döring M, Schulte JH, Bader P, Schlegel PG, Eyrich M, Lang P, Klingebiel T, Handgretinger R.
Flaadt T, et al. Among authors: lang p.
Cancers (Basel). 2025 Jan 5;17(1):149. doi: 10.3390/cancers17010149.
Cancers (Basel). 2025.
PMID: 39796776
Free PMC article.